Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
Frederick Varricchio(Center for Biologics Evaluation and Research), Robert T. Chen(The Task Force for Global Health), Robert Ball(Center for Drug Evaluation and Research), John Iskander, M. Miles Braun(Center for Biologics Evaluation and Research), Frank DeStefano(Abbott Fund), Robert Pless
Cited by 379
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448